Potential of gold-bound microtubules as a new ultrasound contrast agent

Contrast agents based on gas-filled microspheres share the problem of time limited opacification due to low stability of microbubbles. The aim of this study was to test if gold-bound microtubules provide backscattering that allows microtubules to be potentially useful as an ultrasound (US) contrast agent. Gold colloids were immobilized on protein microtubule walls. Latex balloons were filled with gold-bound microtubules or conventional left heart contrast agent and were ultrasonographically imaged in fundamental and harmonic modes. Feasibility of anti-beta-tubulin antibody conjugation to gold-bound microtubules was confirmed using immune fluorescence analysis. Gold particles were successfully bound to microtubules. Contrast intensities in latex balloons filled with gold-bound microtubules (141 +/- 35) were comparable to those with Levovist (180 +/- 35) and did not decrease significantly during continuous US imaging for 20 min (135 +/- 34 vs. Levovist 5.0 +/- 2.0). Anti-beta-tubulin antibodies were successfully conjugated to gold-bound microtubules. Gold-bound microtubules provide a persistent contrast effect, suggesting their use as an ultrasonic contrast agent with the feasibility of antibody conjugation.     

Human monocyte colony-stimulating factor stimulates the gene expression of monocyte chemotactic protein-1 and increases the adhesion of monocytes to endothelial monolayers.

The stimulation of the human umbilical vein endothelial cell (HUVEC) with recombinant human monocyte-derived colony-stimulating factor (MCSF) increased the gene expression of monocyte chemotactic protein (MCP-1). Northern blot analysis indicated that 50 U/ml of MCSF is the optimal concentration for this effect. The elevation of MCP-1 mRNA started as early as 1 h after stimulation and was maintained for at least 8 h. An increased MCP-1 level in MCSF-treated HUVEC was also demonstrated at the protein level by immunocytochemical staining using a polyclonal MCP-1-specific antibody. HUVEC activated by 50 U/ml of MCSF for 5 h showed a stronger immunofluorescence staining than control cells. Micropipette separation of THP-1 monocytes from HUVEC showed that the activation of both THP-1 and endothelium by MCSF led to an increase in the separation force by more than three times (36.2 +/- 6.7 x 10(-4) vs. 9.6 +/- 3.6 x 10(-4) dyn). An increased adhesiveness was also observed after MCSF activation of peripheral blood monocytes and HUVEC (16.7 +/- 2.7 x 10(-4) vs. 5.2 +/- 0.9 x 10(-4) dyn). The increased adhesive force in both systems was blocked by the use of anti-MCP-1 (5.5 +/- 0.8 x 10(-4) and 6.8 +/- 1.1 x 10(-4) dyn). Similar results were obtained in experiments in which only HUVEC, but not monocytes, were activated by MCSF. This increased adhesion of untreated monocytes to MCSF-activated HUVEC was also blocked by the addition of anti-MCP-1. In contrast, experiments in which only THP-1 or peripheral blood monocytes, but not HUVEC, were treated with MCSF did not show a significant increase of adhesion between these cells. These results indicate that MCSF augments monocyte-endothelium interaction primarily by its action on the endothelial cell and that this function is probably mediated through an increased expression of MCP-1. The MCSF/MCP-1-dependent adhesive mechanism might be operative in the arterial wall in vivo to lead to the trapping of the infiltrated monocyte-macrophage in the subendothelial space during atherogenesis.     

Binding of tissue plasminogen activator to cultured human endothelial cells.

Tissue plasminogen activator (t-PA) and urokinase (u-PA), the major activators of plasminogen, are synthesized and released from endothelial cells. We previously demonstrated specific and functional binding of plasminogen to cultured human umbilical vein endothelial cells (HUVEC). In the present study we found that t-PA could bind to HUVEC. Binding of t-PA to HUVEC was specific, saturable, plasminogen-independent, and did not require lysine binding sites. The t-PA bound in a rapid and reversible manner, involving binding sites of both high (Kd, 28.7 +/- 10.8 pM; Bmax, 3,700 +/- 300) and low (Kd, 18.1 +/- 3.8 nM; Bmax 815,000 +/- 146,000) affinity. t-PA binding was 70% inhibited by a 100-fold molar excess of u-PA. When t-PA was bound to HUVEC, its apparent catalytic efficiency increased by three- or fourfold as measured by plasminogen activation. HUVEC-bound t-PA was active site-protected from its rapidly acting inhibitor: plasminogen activator inhibitor. These results demonstrate that t-PA specifically binds to HUVEC and that such binding preserves catalytic efficiency with respect to plasminogen activation. Therefore, endothelial cells can modulate hemostatic and thrombotic events at the cell surface by providing specific binding sites for activation of plasminogen.     

超声介导携RGDS靶向超声造影剂对体外血栓的助溶研究

目的探讨携RGDS的脂膜氟烷超声造影剂（亲血栓靶向超声造影剂）对体外血栓的助溶效果。方法健康人体新鲜静脉血块60份，分为3组，分别加入亲血栓靶向超声造影剂、非靶向超声造影剂和生理盐水进行超声消融；采用超声治疗仪，选择1．2W／cm^2，距离3cm，治疗时间15min。称量溶栓前后血块的质量，组间比较采用t检验。电镜扫描经消融后的血块表面结构。结果经超声介导造影剂助溶前后的血块质量组间比较差异均有统计学意义（P〈0．01）。电镜扫描显示，生理盐水组血块经消融后表面结构无明显改变，靶向超声造影剂组可见大量均匀分布的空洞和裂隙，非靶向超声造影剂组仅见少量分布的小型凹陷及微小裂隙。结论治疗超声介导下的超声造影剂具有助溶作用，血栓靶向超声造影剂较非靶向超声造影剂具有更强的助溶效果。     

Importance of factor Xa in determining the procoagulant activity of whole-blood clots.

The binding of thrombin to fibrin is thought to be an important mechanism by which thrombi exhibit procoagulant activity; however, the extent to which other procoagulants are associated with thrombi has not been previously defined. This study was designed to determine whether clotting factors other than thrombin are bound to whole-blood clots and can thereby contribute to significant procoagulant activity. Clots formed in vitro from human blood exhibited minimal thrombin activity when incubated in plasma depleted of vitamin K-dependent factors by barium-citrate adsorption, as indicated by increases in the concentration of fibrinopeptide A (FPA), a marker of fibrin formation, to 72 nM after 30 min. Incubation of clots in barium-absorbed plasma repleted with 0.9 microM human prothrombin under the same conditions resulted in marked increases in the concentration of FPA (> 1,000 nM) and clotting by 30 min. The increases in FPA were attributable to activation of the added prothrombin by clot-associated Factor Xa, judging from concomitant increases in the concentration of prothrombin fragment 1.2. Similar results were obtained with thrombi induced in the axillary arteries of dogs by vascular injury and incubated with plasma in vitro. Activation of prothrombin was inhibited in a dose-dependent manner by tick anticoagulant peptide, a direct inhibitor of Factor Xa, at concentrations of 0.5-5.0 microM. Clot-associated Factor Xa activity was resistant to inhibition by anti-thrombin III, judging from the lack of inhibition of prothrombin activation during incubation of clots in plasma containing heparin pentasaccharide, an anti-thrombin III-mediated inhibitor of Factor Xa. Thus, the activity of Factor Xa appears to be an important determinant of the procoagulant activity of whole-blood clots and arterial thrombi, and is resistant to inhibition by anti-thrombin III-dependent inhibitors.     

Enhancement of fibrinolysis in vitro by ultrasound.

The effect of ultrasound on the rate of fibrinolysis has been investigated using an in vitro system. Plasma or blood clots containing a trace label of 125I fibrin were suspended in plasma containing plasminogen activator and intermittently exposed to continuous wave 1-MHz ultrasound at intensities up to 8 W/cm2. Plasma clot lysis at 1 h with 1 microgram/ml recombinant tissue plasminogen activator (rt-PA) was 12.8 +/- 1.2% without ultrasound and was significantly (P = 0.0001) increased by exposure to ultrasound with greater lysis at 1 W/cm2 (18.0 +/- 1.4%), 2 W/cm2 (19.3 +/- 0.7%), 4 W/cm2 (22.8 +/- 1.8%), and 8 W/cm2 (58.7 +/- 7.1%). Significant increases in lysis were also seen with urokinase at ultrasound intensities of 2 W/cm2 and above. Exposure of clots to ultrasound in the absence of plasminogen activator did not increase lysis. Ultrasound exposure resulted in a marked reduction in the rt-PA concentration required to achieve an equivalent degree of lysis to that seen without ultrasound. For example, 15% lysis occurred in 1 h at 1 microgram/ml rt-PA without ultrasound or with 0.2 microgram/ml with ultrasound, a five-fold reduction in concentration. Ultrasound at 1 W/cm2 and above also potentiated lysis of retracted whole blood clots mediated by rt-PA or urokinase. The maximum temperature increase of plasma clots exposed to 4 W/cm2 ultrasound was only 1.7 degrees C, which could not explain the enhancement of fibrinolysis. Ultrasound exposure did not cause mechanical fragmentation of the clot into sedimentable fragments, nor did it alter the sizes of plasmic derivatives as demonstrated by SDS polyacrylamide gel electrophoresis. We conclude that ultrasound at 1 MHz potentiates enzymatic fibrinolysis by a nonthermal mechanism at energies that can potentially be applied and tolerated in vivo to accelerate therapeutic fibrinolysis.     

Effect of externally applied focused acoustic energy on clot disruption in vitro.

Application of low-frequency ultrasound for clot disruption has been suggested as a potential therapy to enhance thrombus dissolution, but the optimal mode for delivery of ultrasound with clot-disruptive properties has not yet been extensively explored. Target-specific effects are desirable and may be accomplished by focusing the ultrasound. Adequate focusing, however, requires a short wavelength. The aim of this study was to compare the clot-disruptive effects of different modalities of focused acoustic energy. An in vitro model (10 blood clots for each modality) was used to test the clot-disruptive capacity of (i) shock waves generated in an electrohydraulic lithotriptor; (ii) focused continuous ultrasound of frequency 1.1 MHz, delivered from a specially constructed piezoelectric transducer; and (iii) focused pulse-modulated ultrasound of frequency 1.1 MHz delivered from the same transducer. Exposure to 30 s of focused pulse-modulated ultrasound caused a marked reduction (99+/-2%) in clot weight compared with 30 shock waves (11+/-5%) or 30 s exposure to focused continuous wave ultrasound (11+/-6%) (P<0.0001). The observed marked and rapid disruptive effect on blood clots of focused high-frequency ultrasound indicates an alternative approach for external ultrasound-mediated thrombus destruction in vivo. The focused pulse-modulated technique has potential to exhibit the desired effect in a well-defined target volume and provides the means for control of the average power.     

Prototype therapeutic ultrasound emitting catheter for accelerating thrombolysis.

The aim of this study was to evaluate the performance of a new therapeutic ultrasound device for accelerating thrombolysis by urokinase. Artificial thrombi were produced in vitro by Chandler's loop method. Urokinase (240 IU) was added to the artificial thrombi (n = 5) before exposure to ultrasound with the new catheter-delivered device. Ultrasound (1.3 MHz) was applied with an intensity of 0.3 W/cm2 for 60 s. The degree of fibrinolysis was obtained by measurement of thrombus weight and calculated as percentages. Fibrinolysis was compared between control thrombus groups (n = 5) treated with urokinase alone or with ultrasound alone (analysis of variance, P < 0.05). Ultrasound plus urokinase (33.1 +/- 6.1% [mean +/- standard deviation]) was significantly different urokinase alone (12.3 +/- 2.4%) after 15 min of incubation. Ultrasound alone resulted in no fibrinolysis (0.9 +/- 2.5%). Ultrasound energy from the catheter-based device was sufficient to induce acceleration of fibrinolysis with urokinase.     

The 4G/5G PAI-1 polymorphism influences the endothelial response to IL-1 and the modulatory effect of pravastatin

BACKGROUND: Increased plasminogen activator inhibitor (PAI-1) levels lead to impaired fibrinolytic function associated with higher cardiovascular risk. PAI-1 expression may be regulated by different inflammatory cytokines such as interleukin-1alpha (IL-1). Several polymorphisms have been described in the PAI-1 gene. AIM: We examined the influence of the 4G/5G polymorphism in the promoter region on IL-1alpha-induced PAI-1 expression by human umbilical vein endothelial cells (HUVEC) in presence or absence of pravastatin. METHODS AND RESULTS: Genotyped HUVEC were incubated with IL-1alpha (500 U mL(-1)) in presence or absence of pravastatin (1-10 microm). PAI-1 expression was analyzed by real time polymerase chain reaction (PCR), and PAI-1 antigen measured in supernatants by ELISA. IL-1alpha increased PAI-1 secretion in a genotype-dependent manner, and higher values were observed for 4G/4G compared with both 4G/5G and 5G/5G cultures (P < 0.05). Preincubation of HUVEC with 10 microm pravastatin significantly reduced IL-1-induced PAI-1 expression in 4G/4G HUVEC compared with untreated cultures (177.5% +/- 24.5% vs. 257.9% +/- 39.0%, P < 0.05). Pravastatin also attenuated the amount of secreted PAI-1 by 4G/4G HUVEC after IL-1 stimulation (5020.6 +/- 165.7 ng mL(-1) vs. 4261.1 +/- 309.8 ng mL(-1), P < 0.05). This effect was prevented by coincubation with mevalonate, indicating a dependence on HMG-CoA reductase inhibition. CONCLUSIONS: The endothelial 4G/5G PAI-1 genotype influences the PAI-1 response to IL-1alpha and the modulatory effect of pravastatin. As increased PAI-1 levels have been linked to cardiovascular disease the observed endothelial modulation by pravastatin may have potential clinical implications.     

多发性骨髓瘤细胞脑源性神经营养因子对血管新生作用的研究

目的研究多发性骨髓瘤(MM)细胞脑源性神经营养因子(BDNF)的表达水平及其与MM细胞诱导的血管新生的关系。方法采用RT-PCR法、Western blot法及ELISA法检测MM细胞系KM3、RPMI8226细胞BDNF的表达及分泌。采用MTT法观察MM细胞培养上清液对脐静脉内皮细胞(HUVEC)增殖的作用;用改良的Boyden小室法观察MM细胞培养上清液对HUVEC迁移的影响;采用体外小管形成实验,观察MM细胞培养上清液对HUVEC分化的影响。结果KM3、RPMI8226细胞不仅表达BDNF mRNA,也表达和分泌BDNF蛋白,BDNF的基础分泌水平在其生物学作用范围内。KM3、RPMI8226细胞培养上清液均可明显促进HUVEC增殖,含50.0%KM3细胞培养上清液组和完全KM3细胞培养上清液组HUVEC数分别为对照组的(1.85±0.23)倍和(2.16±0.29)倍(P<0.05),抗人类BDNF中和抗体可部分抑制其促增殖活性;含50.0%KM3细胞培养上清液组HUVEC迁移指数为1.85±0.23,完全KM3细胞培养上清液组HUVEC迁移指数为2.16±0.29,与对照组比较,差异有统计学意义(P值均<0.05),并可明显促进基质胶中网状毛细血管形成(P<0.01),抗BDNF中和抗体可明显抑制其作用。结论MM细胞表达和分泌BDNF,BDNF可能参与MM细胞诱导的血管新生。     

Molecular imaging of vascular endothelial growth factor receptor 2 expression using targeted contrast-enhanced high-frequency ultrasonography.

OBJECTIVE: The aim of our study was to investigate the use of targeted contrast-enhanced high-frequency ultrasonography for molecular imaging of vascular endothelial growth factor receptor 2 (VEGFR2) expression on tumor vascular endothelium in murine models of breast cancer. METHODS: Highly invasive metastatic (4T1) and nonmetatstatic (67NR) breast cancer cells were implanted in athymic nude mice. Tumors were examined in vivo with targeted contrast-enhanced high-frequency ultrasonography using a scanner with a 40-MHz probe. Randomized boluses of ultrasound contrast agents (UCAs) conjugated with an anti-VEGFR2 monoclonal antibody or an isotype control antibody (immunoglobulin G) were injected into the animals. Sonograms were analyzed by calculation of the normalized video intensity amplitudes caused by backscatter of the bound UCA. After ultrasonography, the tumor samples were harvested for analysis of VEGFR2 expression by immunoblotting and immunocytochemistry. RESULTS: The mean video intensity amplitude caused by backscatter of the retained VEGFR2-targeted UCA was significantly higher than that of the control UCA (mean +/- SD: 4T1 tumors, 15 +/- 3.5 versus 7 +/- 1.6 dB; P < .01; 67NR tumors, 50 +/- 12.3 versus 12 +/- 2.6 dB; P < .01). There was a significant difference in VEGFR2-targeted UCA retention between 4T1 and 67NR tumors (normalized video intensity amplitudes, 15 +/- 3.5 and 50 +/- 12.3 dB, respectively; P < .001), and this correlated well with relative VEGFR2 expression in the two tumor types. CONCLUSIONS: Targeted contrast-enhanced high-frequency ultrasonography may enable in vivo molecular imaging of VEGFR2 expression on the tumor vascular endothelium and may be used for noninvasive longitudinal evaluation of tumor angiogenesis in preclinical studies.     

Voltage sensitivity response of ultrasonic hydrophones in the frequency range 0.25-2.5 MHz

Frequency responses of different PVDF polymer hydrophones, including membrane and needle designs, were measured and are presented in terms of end-of-cable voltage sensitivity vs. frequency over a wide, 4.5-octave bandwidth ranging from 0.25-2.5 MHz. The experimental data indicate that the membrane PVDF hydrophones can exhibit uniform, to within +/- 0.75 dB, responses. However, a widely used bilaminar membrane hydrophone-preamplifier combination may display sensitivity variations of +/- 2 dB. Also, even well-designed needle-type hydrophones show a more distinct sensitivity variation below 1 MHz that is on the order of 3-4 dB. The overall uncertainty of the calibration technique was estimated to be better than +/- 2 dB in the frequency range considered. The technique, which uses a combination of swept frequency chirp and reciprocity so that both the relative and absolute plots of sensitivity vs. frequency can be obtained, is also briefly described. The results of this work are important to implement procedures for adequate determination of the mechanical index of ultrasound (US) imaging devices. Mechanical index is widely accepted as a predictor of potential bioeffects associated with cavitation phenomena. Also, absolute calibration data are essential in development of therapeutic procedures based on the use of high-intensity focused ultrasound (HIFU), and in characterization of conventional therapeutic US applicators operating at frequencies below 1 MHz.     

Estimating myocardial attenuation from M-mode ultrasonic backscatter

The objective of this investigation was to determine whether measurements of myocardial attenuation can be obtained from analyses of M-mode images. We exploited the inherent anisotropy of myocardial properties as a means of systematically varying the attenuation to evaluate this M-mode image-based method for myocardial tissue characterization. A commercially available ultrasonic imaging system was used to acquire M-mode images of 24 excised cylindrical specimens from six formalin-fixed sheep hearts that were analyzed using video signal analysis. Data were compensated for the presence of bright intramural myocardial echoes, a potentially significant contributor to uncertainty in measurements of attenuation from backscattered ultrasound. The estimated attenuation coefficient in dB/cm at an effective center frequency of 2.75 MHz as a function of angle of insonification for measurements obtained from analyses of M-mode images is presented. Given a linear frequency-dependence of attenuation in myocardial tissue over frequencies ranging from 1.5 MHz to 8 MHz, as has been previously reported, M-mode image-based analyses were used to estimate the slope of attenuation. Results showed slopes of attenuation (over a -10 dB transmit bandwidth of 1.875 MHz to 3.75 MHz) ranging from 1.00 +/- 0.07 to 1.81 +/- 0.08 dB/(cm.MHz) for perpendicular and parallel insonification, respectively. These values were in good agreement with contemporaneously measured values (0.99 +/- 0.02 to 1.77 +/- 0.04 dB/(cm.MHz)) obtained over a frequency bandwidth of 4 MHz to 7 MHz using a through-transmission radio-frequency-based approach. These data suggest that robust measurements of myocardial attenuation can be obtained from analyses of M-mode images and that this method may be diagnostically feasible in the clinical setting.     

Endothelium-derived microparticles inhibit human cardiac valve endothelial cell function

Elevated numbers of endothelium-derived microparticles (EMPs) in the circulation are found in a variety of critical illnesses. EMPs have been associated with vascular dysfunction, including thrombotic complications and loss of normal vascular reactivity, common responses associated with cardiac valve injury. However, the exact mechanisms of this dysfunction and the potential impact on cardiac endothelium are unknown. We hypothesize that pathologic levels of circulating EMPs negatively regulate proliferation and migration of valvular endothelial cells (ECs), leading to downstream endothelial dysfunction. EMPs were generated from plasminogen activation inhibitor 1-stimulated human umbilical vein endothelial cells (HUVECs). Human mitral valve endothelial cells (HMVECs) were isolated and characterized by platelet endothelial cell-derived adhesion molecule-1 (PECAM-1, or CD31) and von Willebrand factor immunocytochemistry. HMVECs were treated with increasing EMP doses, and then, the effects of EMPs on growth factor-induced proliferation and migration were tested. Proliferation was assessed by H-thymidine incorporation. EC migration was assayed by photographing microtubules of HMVECs and HUVECs in fibrin gel incubated with EMPs +/- growth factors for 48 h. The EMP effects on non-valve HUVECs were tested in parallel. EMPs inhibited HMVEC proliferation at high doses but stimulated HUVEC proliferation at all doses. In HMVECs, EMPs inhibited basic fibroblast growth factor- and vascular endothelial growth factor-induced proliferation and migration. Taken together, these data suggest EMPs regulate valvular EC proliferation in a dose-dependent manner and, furthermore, modulate growth factor signaling in ECs. These results implicate EMPs as a possible source of downstream EC dysfunction in disease states. EMPs may play a role in valvular leaflet injury in human disease by inhibiting normal growth and repair of endothelium.     

结合链霉亲和素的高分子造影剂的制备及其初步应用

目的 制备一种结合链霉亲和素的高分子超声造影剂,并与生物素化抗体结合,考察其体外寻靶能力.方法 采用双乳化法制备高分子材料PLGA-COOH超声造影剂;并用碳二亚胺法将造影剂与亲和素耦联,制备出结合链霉亲和素的高分子超声造影剂.检测该造影剂一般特性;采用红外与免疫荧光检测亲和素与PLGA-COOH超声造影剂连接的情况.检测生物素-亲和素技术使该造影剂与生物素化抗体结合后其体外寻靶能力.结果 红外检测与免疫荧光检测显示亲和素被成功地连接在高分子造影剂上,并存在活性.体外寻靶实验显示,与生物素化单抗结合后的靶向高分子造影剂较多并牢固地聚集到肝癌细胞表面.结论 成功制备了结合链霉亲和素的高分子超声造影剂,该造影剂与生物素化抗体结合后于体外对肝癌细胞具有较强的亲和力.     

The ability of quantitative ultrasound at the calcaneus to identify postmenopausal women with different types of nontraumatic fractures

The aim of the cross-sectional study was to determine if ultrasound (US) measurements of the calcaneus have the ability to predict the risk for fractures and to discriminate between postmenopausal women with and without different types of nontraumatic fractures. All women (n = 1,129, age range 40 to 87 years) were divided into group 1, created by 656 women with 956 nontraumatic past fractures, and group 2, consisting of 473 women without fractures. Group 1 was divided into subgroups: with hip fractures, with vertebral (nonhip) fractures, with wrist (nonhip and nonspine) fractures and with other (nonhip, nonspine and nonwrist) fractures. The speed of sound (SOS; m/s) and broadband ultrasound attenuation (BUA; dB/MHz) were measured with the Achilles system (Lunar), which also calculates stiffness index (SI; %). US values were significantly lower in group 1 (1,481.4 +/- 20.2 m/s, 98.7 +/- 9.4 dB/MHz, 61.1 +/- 11.0%; p < 0.000001) and in subgroups (p < 0.000001), and these women had a higher mean age and longer postmenopausal period than women without fractures (1508.2 +/- 26.5 m/s, 107.7 +/- 9.9 dB/MHz, 74.2 +/- 13.0%). Women with hip fractures had the lowest US values (1464.6 +/- 18.6 m/s, 89.9 +/- 8.7 dB/MHz, 50.6 +/- 10.5%), women with vertebral fractures had intermediate values (1473.6 +/- 17.4 m/s, 94.8 +/- 8.9 dB/MHz, 56.4 +/- 10.0%), and women with wrist (1,484.3 +/- 19.8 m/s, 99.9 +/- 9.3 dB/MHz, 62.7 +/- 10.7%) and other fractures (1,483.3 +/- 21.0 m/s, 100.4 +/- 8.6 dB/MHz, 62.7 +/- 10.6%) had the highest values. The US values differed significantly between subgroups with fractures (p < 0.05), with no significant differences between women with wrist and other fractures. ROC analysis showed SOS to have the best sensitivity and specificity in detecting fracture cases. All US parameters revealed the greatest areas under the ROC curve (AUCs) for hip fracture (0.92 to 0.93) in comparison to smaller AUCs for vertebral fractures (ranging from 0.84 to 0.87), and the smallest AUCs for wrist and other fractures (ranging from 0.72 to 0.77 and 0.72 to 0.78, respectively). Generally, the SOS measurement presented greater odds ratio (OR) than BUA and SI: 4.1 (3.09 to 5.43) for any fracture, 11.66 (3.09 to 43.96) for hip fracture, 6.51 (3.61 to 11.73) for vertebral fracture, 3.32 (2.41 to 4.58) for wrist fracture and 4.2 (2.7 to 6.54) for other fracture. The present study demonstrates the ability of calcaneal QUS to discriminate between healthy individuals and subjects with different types of nontraumatic fractures. Calcaneal US parameters show the best sensitivity and specificity in discriminating the hip fracture patients from the controls. Generally, the SOS parameter is a better discriminator than SI and BUA and estimates the highest OR for fractures.     

A thin-walled carotid vessel phantom for Doppler ultrasound flow studies

A technique is discussed for producing a robust ultrasound (US)-compatible flow phantom that consists of a thin-walled silicone-elastomer vessel with a lumen of arbitrary geometry, embedded in an agar-based tissue-mimicking material (TMM). The TMM has an acoustic attenuation of 0.56 dB cm(-1) MHz(-1) at 5 MHz, with nearly linear frequency-dependence and acoustic velocity of 1539 +/- 4 m s(-1). The vessel-mimicking material (VMM) has an acoustic attenuation of 3.5 dB cm(-1) MHz(-1) with linear frequency-dependence and an acoustic velocity of 1020 +/- 20 m s(-1). Scattering particles, which are added to the VMM to increase echogenicity and add speckle texture, lead to higher attenuation, depending on particle concentration and frequency. The VMM is stable over time, with a Young's elastic modulus of 1.3 to 1.7 MPa for strains of up to 10%, which mimics human arteries under typical physiological conditions. The phantom is sealed to prevent TMM exposure to air or water, to avoid changes to the acoustic velocity.     

Intermittent flow increases endotoxin-induced adhesion of human erythrocytes to vascular endothelial cells

OBJECTIVE: To investigate the effects of different conditions of flow on endotoxin induced adhesion of human red blood cells (RBC) to human umbilical vein endothelial cells (HUVEC). DESIGN AND SETTING: Prospective, randomized, controlled in vitro study in a university-affiliated cell biology laboratory. SUBJECTS. Human erythrocytes, human vascular endothelial cells. INTERVENTIONS: Superfusion of HUVEC monolayers with human erythrocytes incubated with either saline (CON) or endotoxin (ETX) with different flow pattern (basic flow rates of 0.65 or 1.3 ml/min; intermittent flow, IMF). The CON/0.6, CON/1.3, CON-IMF/1.3 ( n=7/group) groups served as control, and in test groups ETX/0.6, ETX/1.3, ETX-IMF/0.6, and ETX-IMF/1.3 ( n=7/group) both RBC and HUVECs were incubated with ETX and flow pattern and rates varied. In the IMF experiments flow rates of 0.65 and 1.3 ml/min were combined with stop-and-go flow pattern. MEASUREMENTS AND RESULTS: At continuous flow of 0.65 ml/min erythrocyte adhesion was 61+/-5 cells/mm(2) in CON and 172+/-25 cells/mm(2) after ETX. When flow rate was increased to 1.3 ml/min, adhesion decreased to 27+/-4 cells/mm(2) in CON and 93+/-18 cells/mm(2) after ETX. IMF conditions had no effect on RBC adhesion of naive RBC but increased the number of adhesive erythrocytes after incubation with ETX both at 0.65 ml/min (287+/-33 cells/mm(2)) and at 1.3 ml/min (148+/-13 cells/mm(2)). CONCLUSIONS: RBC adhesion to vascular endothelium is affected by rate and pattern of blood flow. Higher flow rates or shear forces reduce RBC adhesion while stop-and-go flow pattern favored adhesion of ETX-treated erythrocytes to HUVECs. These findings suggest that altered RBCs interact with altered flow patterns potentially contributing to the microcirculatory injury observed in sepsis.     

A critical role for monocytes and CD14 in endotoxin-induced endothelial cell activation

Vascular endothelium activated by endotoxin (lipopolysaccharide [LPS]) and cytokines plays an important role in organ inflammation and blood leukocyte recruitment observed during sepsis. Endothelial cells can be activated by LPS directly, after its interaction with LPS-binding protein and soluble CD14 in plasma. LPS-LPS-binding protein complexes in blood also interact with monocytes and neutrophils bearing glycosyl- phosphatidylinositol (GPI) anchored membrane CD14 (mCD14), promoting the release of cytokines such as tumor necrosis factor and interleukin 1 (IL-1). These molecules, in turn, have the capacity to activate endothelial cells providing an indirect pathway for LPS-dependent endothelial cell activation. In this work, we address the relative importance of the direct and the indirect pathway of in vitro LPS- induced human umbilical vein endothelial cell (HUVEC) activation. Substituting whole blood for plasma resulted in a 1,000-fold enhancement of HUVEC sensitivity to LPS. Both blood- and plasma- dependent enhanced activation of HUVEC were blocked with an anti-CD14 monoclonal antibody. Blood from patients with paroxysmal nocturnal hemoglobinuria, whose cells lack mCD14 and other GPI anchored proteins, was unable to enhance LPS activation of HUVEC above the level observed with plasma alone. IL-10, an inhibitor of monocyte release of cytokines, decreased the blood-dependent enhancement of HUVEC activation by LPS. Blood adapted to small doses of LPS was also less efficient than nonadapted blood in producing this enhancement. Addition of purified mononuclear cells to HUVEC or the transfer of plasma from whole blood incubated with LPS to HUVEC, duplicated the enhancement effect observed when whole blood was incubated with HUVEC. Taken together, these data suggest that the indirect pathway of LPS activation of endothelial cell is mediated by monocytes and mCD14 through the secretion of a soluble mediator(s). The indirect pathway is far more efficient than the direct, plasma-dependent pathway.     

Examination of cancer in mouse models using high-frequency quantitative ultrasound

Two mouse models of mammary cancer (a carcinoma and sarcoma) were examined using quantitative ultrasound (QUS). Scatterer property estimates, i.e., the average scatterer diameter (ASD) and average acoustic concentration (AAC), were estimated from regions-of-interest (ROIs) inside the tumors. Initially, the spherical Gaussian model was used over an analysis bandwidth of 10 to 25 MHz to obtain ASD and AAC estimates. ASD estimates were 31.7 +/- 9.36 microm and 31.0 +/- 7.20 microm for the carcinomas and sarcomas, respectively. AAC estimates were 6.77 +/- 8.75 dB[mm(-3)] and 9.87 +/- 9.24 dB[mm(-3)], respectively. The initial ASD and AAC estimates did not yield statistically significant differences between the two kinds of tumors (p = 0.83, 0.86 for the ASD and AAC estimates, respectively). However, optical photomicrographs revealed distinct morphologic differences between the tumors. F-tests on the average power spectra from the tumors revealed statistically significant differences between the spectra over the range of 16 to 25 MHz. ASD and AAC estimates using the spherical Gaussian model were then obtained over the new analysis bandwidth of 16 to 25 MHz. The new ASD estimates were 42.1 +/- 4.01 microm and 32.1 +/- 3.81 microm for the carcinomas and sarcomas, respectively. The new AAC estimates were 16.4 +/- 17.1 dB[mm(-3)] and 36.4 +/- 11.9 dB[mm(-3)], respectively. Statistically significant differences were observed for both the ASD and AAC estimates when using the new analysis bandwidth. Structural differences between the tumors were revealed by both QUS and optical photomicrographs.